Endocare Inc.

The Irvine developer of temperature-based surgical devices and technologies, including treatments for prostate cancer, posted a net loss of $2.3 million, or 21 cents a share, for the fourth quarter, compared with a net loss of $1.5 million, or 14 cents a share, for the same quarter a year ago. Revenue increased 94% to a record $1.2 million. For the year, the company reported a net loss of $9.3 million, or 86 cents a share, compared with a year-earlier net loss of $4.9 million, or 49 cents a share. Revenue advanced 40% to $3.5 million.